X-ACKT: XEN1101 as adjunctive therapy in primary generalized tonic-clonic seizures

Phase 3, randomised, double-blind trial in generalized tonic-clonic seizure (GTCS) and generalized epilepsy comparing XEN1101 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Proportion of subjects with ≥50% reduction in monthly PGTCS frequency. Planned start Jun 2023; status: authorised.